Actively Recruiting

Phase 1
Age: 21Years - 70Years
All Genders
NCT05322213

THC Effects on Glucose in Type 2 Diabetes

Led by University of California, San Diego · Updated on 2025-05-07

30

Participants Needed

1

Research Sites

197 weeks

Total Duration

On this page

Sponsors

U

University of California, San Diego

Lead Sponsor

C

Center for Medicinal Cannabis Research

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study will examine the effects THC has on Glucose Metabolism and Endothelial Functioning in participants with Type 2 Diabetes. The participants will complete blood tests and tests to measure energy expenditure, CVD risks, and glucose metabolism. These tests will be performed prior to start of treatment and again after 2-weeks of treatment with the THC or placebo.

CONDITIONS

Official Title

THC Effects on Glucose in Type 2 Diabetes

Who Can Participate

Age: 21Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Males and females aged 21 to 70 years at screening
  • Females of non-childbearing potential must be at least 1 year post-menopausal or surgically sterile
  • Females of childbearing potential must agree to use two forms of contraception during the study
  • Males must agree to use an acceptable method of contraception during the study
  • Clinical diagnosis of Type 2 Diabetes with stable medication regimen for at least 3 months
  • Body mass index greater than 25 kg/m2
  • HbA1c less than 10%
  • Negative urine toxicology at screening
  • Able to provide written informed consent approved by an Institutional Review Board
Not Eligible

You will not qualify if you...

  • History or presence of significant illness increasing risk of adverse events (e.g., psychotic disorder, mood or anxiety disorder, liver or kidney disease)
  • Prior history of myocardial infarction, stroke, or heart failure
  • Whole blood donation of 500 mL or more within 8 weeks before screening
  • Hemoglobin less than 9 g/dL
  • Liver enzymes twice the normal limit or clinical signs of liver disease
  • History of severe adverse events related to cannabis intoxication
  • History of seizures, head trauma, or central nervous system conditions predisposing to seizures
  • Use of THC products within 30 days before screening
  • Current tobacco use
  • Pregnant or breastfeeding individuals
  • Current use of insulin for Type 2 Diabetes
  • Unable or unwilling to follow study protocol or attend visits
  • Any other condition that might affect study data or participant safety or informed consent ability

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UC San Diego Altman Clinical & Translational Research Institute

La Jolla, California, United States, 92037

Actively Recruiting

Loading map...

Research Team

T

Todd May, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here